EML4 and chronic myelogenous leukemia, BCR-ABL1 positive: To assess performance of the INKA approach, pTyr IP‐based phosphoproteomic data were generated and analyzed for four well‐studied cell lines with known oncogenic driver kinases: K562 chronic myeloid leukemia (CML) cells (BCR‐ABL fusion), SK‐Mel‐28 melanoma cells (mutant BRAF), HCC827‐ER3 lung carcinoma cells (mutant EGFR), and H2228 lung carcinoma cells (EML4‐ALK fusion).